- Eli Lilly, the US drugmaker, said it is partnering with the Bill & Melinda Gates Foundation to supply its COVID-19 antibody therapy to low- and middle-income countries.
- The announcement came moments before US President Donald Trump said he would approve Eli Lilly’s antibody treatment in the US.
- Eli Lilly is seeking an emergency use authorization from the Food and Drug Administration (FDA).
- The company said that it would aim to distribute the therapy to low-income countries before April 2021, depending on when the drug was approved in different nations.
- Visit Business Insider’s homepage for more stories.
Drugmaker Eli Lilly has announced that it has partnered with the Bill & Melinda Gates Foundation to supply its COVID-19 antibody therapy to low- and middle-income countries.
The agreement is part of the COVID-19 Therapeutics Accelerator, an initiative launched by the Gates Foundation, Mastercard, and Wellcome to accelerate the development of and access to